title: The impact of histology on clinicopathologic outcomes for patients with renal cell carcinoma and venous tumor thrombus: a matched cohort analysis.
abstract: OBJECTIVE
  To evaluate the impact of tumor histology on clinicopathologic outcomes for patients with renal cell carcinoma (RCC) and venous tumor thrombus (VTT).
  
  
  METHODS
  We identified 807 patients with RCC and VTT who underwent nephrectomy at our institution between 1970 and 2008. All pathologic specimens were re-reviewed by a single urologic pathologist. Patients with non-clear cell RCC (non-ccRCC, n = 56) were matched 1:2 to patients with clear cell RCC (ccRCC) VTT based on symptoms at presentation, regional lymph node involvement, distant metastases, tumor thrombus level, nuclear grade, and sarcomatoid differentiation. Survival was estimated using the Kaplan-Meier method and compared with the log-rank test.
  
  
  RESULTS
  The 56 patients with non-ccRCC VTT included 26 papillary, 11 chromophobe, 5 collecting duct tumors, and 14 RCCs not otherwise specified. Compared to unmatched patients with ccRCC VTT (n = 751), patients with non-ccRCC VTT presented with larger tumor size (P = .02), higher nuclear grade (P = .04), and more frequent sarcomatoid differentiation (P <.001) and lymph node invasion (P <.001). However, when patients with non-ccRCC were matched to patients with ccRCC, no significant differences were noted with regard to 5-year metastases-free survival (41% vs 34%, P = .24) or cancer-specific survival (25% vs 27%, P = .97).
  
  
  CONCLUSIONS
  Non-ccRCC VTT is associated with a high rate of adverse pathologic features. Nevertheless, when matched to patients with ccRCC, patients with non-ccRCC VTT did not have increased rate of recurrence or adverse survival. Aggressive surgical resection represents the mainstay of treatment in these cases, whereas continued efforts to optimize a multimodal management approach to such patients remain necessary.
authors: Department of Urology, Mayo Clinic, Rochester, MN, USA.
authors: Dharam
authors: D
authors: Kaushik
authors: Brian J
authors: BJ
authors: Linder
authors: R Houston
authors: RH
authors: Thompson
authors: Manuel S
authors: MS
authors: Eisenberg
authors: Christine M
authors: CM
authors: Lohse
authors: John C
authors: JC
authors: Cheville
authors: Bradley C
authors: BC
authors: Leibovich
authors: Stephen A
authors: SA
authors: Boorjian
mesh_terms: D000368:Aged; D002292:Carcinoma, Renal Cell / Q000473:pathology* / Q000556:secondary / Q000601:surgery; D015331:Cohort Studies; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D007680:Kidney Neoplasms / Q000473:pathology* / Q000601:surgery; D008198:Lymph Nodes / Q000473:pathology; D008297:Male; D016555:Matched-Pair Analysis; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009392:Nephrectomy; D016016:Proportional Hazards Models; D012082:Renal Veins / Q000473:pathology*
references: Eur Urol. 2010 Apr;57(4):667-72
references: 19560258
references: Pathol Res Pract. 2001;197(10):671-5
references: 11700888
references: J Urol. 1987 Jan;137(1):21-4
references: 3795361
references: J Clin Oncol. 2008 Jan 1;26(1):127-31
references: 18165647
references: J Clin Oncol. 2002 May 1;20(9):2376-81
references: 11981011
references: Eur Urol. 2006 Oct;50(4):786-93; discussion 793-4
references: 16697521
references: J Clin Oncol. 2009 Dec 1;27(34):5788-93
references: 19884559
references: Ann Surg Oncol. 2004 Jan;11(1):71-7
references: 14699037
references: J Clin Oncol. 2005 Apr 20;23(12):2763-71
references: 15837991
references: Eur Urol. 2012 Dec;62(6):1013-9
references: 22771265
references: Am J Surg Pathol. 2002 Mar;26(3):281-91
references: 11859199
references: Cancer. 1997 Sep 1;80(5):987-9
references: 9307203
references: J Urol. 2009 Nov;182(5):2132-6
references: 19758615
references: Eur Urol. 2009 Feb;55(2):452-9
references: 18692951
references: Am J Surg Pathol. 2003 May;27(5):612-24
references: 12717246
references: CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29
references: 22237781
references: Cancer. 2008 Apr 1;112(7):1480-8
references: 18240184
references: J Urol. 2000 Apr;163(4):1090-5; quiz 1295
references: 10737472
references: J Immunother. 2005 Sep-Oct;28(5):488-95
references: 16113605
references: Br J Urol. 1987 May;59(5):390-5
references: 3594097
references: Cancer. 2006 Dec 1;107(11):2617-21
references: 17083126
references: Int J Urol. 2008 May;15(5):394-8
references: 18452454
references: J Urol. 2007 Nov;178(5):1896-900
references: 17868729
references: J Urol. 2010 Apr;183(4):1309-15
references: 20171681
references: J Urol. 1978 Jul;120(1):28-31
references: 671600
references: BJU Int. 2007 May;99(5 Pt B):1239-44
references: 17441917
references: J Urol. 2012 Aug;188(2):391-7
references: 22698625
references: BJU Int. 2009 Jun;103(11):1496-500
references: 19076149